Record third quarter 2023 net sales of $4.5 million , an increase of approximately 128% over third quarter 2022 Company increases revenue guidance for full year 2023 to $15.0 million - $15.5 million Company to host a conference call and webcast today, November 8, 2023 at 4:30 PM EST ROCKAWAY, N.J.
Third quarter 2022 revenue grew 33% over third quarter 2021 Company to host a conference call and webcast today, November 3, 2022 at 4:30 pm EDT ROCKAWAY, N.J. , Nov. 03, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced third
Third quarter 2021 revenue grew 17% sequentially and 38% over third quarter 2020 Company to host a conference call and webcast today, November 4, 2021 at 4:30 pm ET ROCKAWAY, N.J. , Nov. 04, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine
Continued growth in prescribing physicians, paid months of therapy and dispensed prescriptions Company to host conference call and webcast today, November 13 , at 4:30pm ET BASKING RIDGE, N.J. , Nov. 13, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic
ROCKAWAY, N.J. , April 08, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the launch of its direct-to-consumer mobile app-enabled product for general wellness, Truvaga Plus, which will be available on
Company anticipates full-year 2021 revenue of approximately $5.5 million, an approximately 55% increase over full-year 2020 ROCKAWAY, N.J. , Jan. 18, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) today published a letter from the company’s Board of Directors to shareholders.
BASKING RIDGE, N.J. , Dec. 01, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that its gammaCore non-invasive vagus nerve stimulator (nVNS) has been selected for evaluation in a randomized controlled study for the
Received EUA and initiated gammaCore Sapphire CV distribution process for certain known or suspected COVID-19 patients experiencing asthma exacerbations Generated sequential increase in revenue Further strengthened balance sheet and reduced quarterly cash burn Company to host conference call and
Record second quarter 2023 net sales of $3.6 million , an increase of approximately 65% over second quarter 2022 Company to host a conference call and webcast today, August 9, 2023 at 4:30 PM EDT ROCKAWAY, N.J. , Aug. 09, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc.
Second quarter 2021 net sales of $1.3 million, increased 69% over second quarter 2020 and 5% sequentially. Company to host a conference call and webcast today, August 5, 2021 at 4:30 pm ET ROCKAWAY, NJ , Aug. 05, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc.